Products Categories
| CAS No.: | 68-22-4 |
|---|---|
| Name: | Norethindrone |
| Article Data: | 47 |
| Molecular Structure: | |
|
|
|
| Formula: | C20H26O2 |
| Molecular Weight: | 298.425 |
| Synonyms: | Norethindrone; |
| EINECS: | 200-681-6 |
| Density: | 1.15 g/cm3 |
| Melting Point: | 205-206 °C(lit.) |
| Boiling Point: | 447 °C at 760 mmHg |
| Flash Point: | 190.5 °C |
| Solubility: | chloroform: ≥50 mg/mL, clear, colorless |
| Appearance: | Off-white to pale yellow solid |
| Hazard Symbols: |
 Xn
|
| Risk Codes: | 40-36/37/38-20/21/22 |
| Safety: | 22-36/37/39-45-26 |
| PSA: | 37.30000 |
| LogP: | 3.49250 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
| Conditions | Yield |
|---|---|
| Stage #1: estra-4-ene-3,17-dione With potassium hydroxide In toluene; tert-butyl alcohol under 760.051 Torr; for 0.166667h; Reflux; Industrial scale; Stage #2: acetylene In tert-butyl methyl ether; toluene for 6h; Industrial scale; | 100% |
| With potassium tert-butylate; acetone |
| Conditions | Yield |
|---|---|
| With potassium In tert-Amyl alcohol; toluene at 20℃; Inert atmosphere; | 88% |
| With potassium 2-methylbutan-2-olate |
- 68-22-4
norethisterone
| Conditions | Yield |
|---|---|
| With potassium hydroxide In methanol; water Ambient temperature; | 86% |
| hydroxide In water at 30℃; Rate constant; Kinetics; Mechanism; other catalysts used; |
| Conditions | Yield |
|---|---|
| With Trichothecium roseum for 288h; Microbiological reaction; | 6.67% |
| Conditions | Yield |
|---|---|
| ueber mehrere Stufen; |
- 19357-36-9
3-methoxy-19-nor-17βH-pregna-2,5(10)-dien-20-yn-17-ol
- 68-22-4
norethisterone
| Conditions | Yield |
|---|---|
| With hydrogenchloride |
| Conditions | Yield |
|---|---|
| With hydrogenchloride; potassium tert-butylate 1.) THF, 1 h, -10 deg C; 2.) MeOH, 60-70 deg C, 2 h; Yield given. Multistep reaction; |
| Conditions | Yield |
|---|---|
| With ammonia |
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: 63 percent / aluminium isopropylate, 2-butanone / benzene / 15 h 2: 1.) K(t-BuO); 2.) conc. HCl / 1.) THF, 1 h, -10 deg C; 2.) MeOH, 60-70 deg C, 2 h View Scheme | |
| Multi-step reaction with 3 steps 1: aluminum isopropoxide; sodium sulfate / methanol; water; cyclohexanone; toluene 2: 1,4-dioxane; methanol; (2S)-N-methyl-1-phenylpropan-2-amine hydrate; ISOPROPYLAMIDE 3: hydrogenchloride / methanol; water View Scheme |
- 75863-04-6
3-Methoxy-6,7:8,9-diseco-1,3,5(10),7-oestratetraen-11,17-dion
- 68-22-4
norethisterone
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 2: 63 percent / aluminium isopropylate, 2-butanone / benzene / 15 h 3: 1.) K(t-BuO); 2.) conc. HCl / 1.) THF, 1 h, -10 deg C; 2.) MeOH, 60-70 deg C, 2 h View Scheme |
What can I do for you?
Get Best Price
Consensus Reports
Specification
Norethindrone is one kind of off-white to pale yellow solid. The IUPAC Name of this chemical is (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one. Its' system names are (1)19-Nor-17-alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-; (2)19-Nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy- (8CI); (3)19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-; (4)Norethisterone. And it belongs to the following product categories: (1)Active Pharmaceutical Ingredients; (2)Acetylenes; (3)Biochemistry; (4)Functionalized Acetylenes; (5)Hydroxyketosteroids; (6)Steroids; (7)Intermediates & Fine Chemicals; (8)Pharmaceuticals. Norethindrone can be manufactured from acetate pregnancy pregnenolone synthesis.
Physical properties about Norethindrone are: (1)ACD/LogP: 2.858; (2)ACD/LogD (pH 5.5): 2.86; (3)ACD/LogD (pH 7.4): 2.86; (4)ACD/BCF (pH 5.5): 87.57; (5)ACD/BCF (pH 7.4): 87.57; (6)ACD/KOC (pH 5.5): 854.94; (7)ACD/KOC (pH 7.4): 854.94; (8)#H bond acceptors: 2; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 1; (11)Index of Refraction: 1.577; (12)Molar Refractivity: 85.551 cm3; (13)Molar Volume: 258.097 cm3; (14)Polarizability: 33.915 10-24cm3; (15)Surface Tension: 49.0810012817383 dyne/cm; (16)Density: 1.156 g/cm3; (17)Flash Point: 190.465 °C; (18)Enthalpy of Vaporization: 81.378 kJ/mol; (19)Boiling Point: 446.98 °C at 760 mmHg
Uses of Norethindrone: It is used in some combined oral contraceptive pills and in some progestogen only pills. It is a progestogen and can be used to treat premenstrual syndrome, painful periods, abnormal heavy bleeding, irregular periods, menopausal syndrome (in combination with oestrogen), or to postpone a period.
When you are using this chemical, please be cautious about it as the following:
1. Do not breathe dust;
2. Wear suitable protective clothing, gloves and eye/face protection;
3. In case of accident or if you feel unwell, seek medical advice immediately (show label where possible);
4. Wear suitable gloves and eye/face protection;
5. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice;
You can still convert the following datas into molecular structure:
(1)InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1;
(2)InChIKey=VIKNJXKGJWUCNN-XGXHKTLJSA-N;
(3)Smiles[C@@H]12[C@@]([C@@](CC2)(C#C)O)(CC[C@H]2[C@H]1CCC1=CC(=O)CC[C@H]21)C;
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | oral | 6gm/kg (6000mg/kg) | Drugs in Japan Vol. -, Pg. 809, 1990. | |
| women | TDLo | oral | 42mg/kg (42mg/kg) | ENDOCRINE: ANDROGENIC SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | American Journal of Obstetrics and Gynecology. Vol. 84, Pg. 962, 1962. |